In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach

References

• Agrawal YO, Mahajan UB, Agnihotri VV, et al. (2021). Ezetimibe-loaded nanostructured lipid carrier based formulation ameliorates hyperlipidaemia in an experimental model of high fat diet. Molecules 26:1485.
   PubMed Web of Science ®Google Scholar
• Ajiboye AL, Nandi U, Galli M, et al. (2021). Olanzapine loaded nanostructured lipid carriers via high shear homogenization and ultrasonication. Sci Pharm 89:25.
   Web of Science ®Google Scholar
• Antonini A, Moro E, Godeiro C, et al. (2018). Medical and surgical management of advanced Parkinson’s disease. Mov Disord 33:900–8.
   PubMed Web of Science ®Google Scholar
• Ashkar A, Sosnik A, Davidovich-Pinhas M. (2021). Structured edible lipid-based particle systems for oral drug-delivery. Biotechnol Adv 54: 107789.
   Google Scholar
• Bampidis V, Azimonti G, Bastos MdL, et al. (2020). Safety and efficacy of sodium carboxymethyl cellulose for all animal species. Efsa J 18:26–31.
   Google Scholar
• Bommaka MK, Mannava MKC, Suresh K, et al. (2018). Entacapone: improving aqueous solubility, diffusion permeability, and cocrystal stability with theophylline. Cryst Growth Des 18:6061–9.
   Web of Science ®Google Scholar
• Chahine LM, Edison B, Daeschler M, et al. (2020). The most bothersome aspects of off periods reported by individuals with Parkinson's disease. Mov Disord Clin Pract 7:284–92.
   PubMed Web of Science ®Google Scholar
• Chalikwar SS, Shirkhedkar AA, Bagul MA, et al. (2012). Development and validation of zero and first-order derivative area under curve spectrophotometric methods for the determination of entacapone in bulk material and in tablets. Pharm Methods 3:14–7.
   PubMedGoogle Scholar
• D’Souza S. (2014). A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm 2014:1–12.
   Google Scholar
• DeMaagd G, Philip A. (2015). Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. PT 40:504–32.
   PubMedGoogle Scholar
• Dorsey ER, Elbaz A, Nichols E, et al. (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:939–53.
   PubMed Web of Science ®Google Scholar
• Forsberg M, Lehtonen M, Heikkinen M, et al. (2003). Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther 304:498–506.
   PubMed Web of Science ®Google Scholar
• Garg N, Joshi R, Medhi B. (2020). A novel approach of targeting refractory epilepsy: need of an hour. Brain Res Bull 163:14–20.
   PubMed Web of Science ®Google Scholar
• Gautam RK, Gupta G, Sharma S, et al. (2019). Rosmarinic acid attenuates inflammation in experimentally induced arthritis in Wistar rats, using Freund’s complete adjuvant. Int J Rheum Dis 22:1247–54.
   PubMed Web of Science ®Google Scholar
• Gonçalves D, Alves G, Soares-da-Silva P, et al. (2012). Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review. Anal Chim Acta 710:17–32.
   PubMed Web of Science ®Google Scholar
• Gordillo-Galeano A, Mora-Huertas CE. (2018). Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm 133:285–308.
   PubMed Web of Science ®Google Scholar
• Gurumukhi VC, Bari SB. (2021). Development of ritonavir-loaded nanostructured lipid carriers employing quality by design (QbD) as a tool: characterizations, permeability, and bioavailability studies. Drug Deliv Transl Res 1–21.
   Web of Science ®Google Scholar
• ICH. (2003). Q1A (R2). Stability testing of new drug substances and products. Geneva: ICH.
   Google Scholar
• Kaakkola S. (2010). Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson’s disease. Int Rev Neurobiol 95:207–25.
   PubMed Web of Science ®Google Scholar
• Khan A, Mudassir J, Akhtar S, et al. (2019). Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics 11:97.
   PubMed Web of Science ®Google Scholar
• Mahmood A, Rapalli VK, Gorantla S, et al. (2021). Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations. Drug Deliv Transl Res 56:71–7.
   Google Scholar
• Müller T. (2020). Entacapone/tolcapone/opicapone for treating Parkinson’s. Disease. NeuroPsychopharmacotherapy 1–18.
   Google Scholar
• Muthu Madaswamy FS-S. (2009). Pharmaceutical stability aspects of nanomedicines editorial. Futur Med 4:857–60.
   PubMed Web of Science ®Google Scholar
• Najib J. (2001). Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson’s disease. Clin Ther 23:802–32.
   PubMed Web of Science ®Google Scholar
• Panda C, Chauhan SP, Balamurugan K. (2020). Formulation and in vitro characterization of raloxifene nanostructured lipid carriers for oral delivery with full factorial design-based studies using Quality By Design (QbD) approach. Int J Res Pharm Sci 11:6417–27.
   Google Scholar
• Patel D, Dasgupta S, Dey S, et al. (2012). Nanostructured lipid carriers (NLC)-based gel for topical delivery of aceclofenac: preparation, characterization and in vivo evaluation. Sci Pharm 80:749–64.
   PubMedGoogle Scholar
• Patil KD, Bagade SB, Bonde SC. (2020). In-vitro and ex-vivo characterization of novel mannosylated gelatin nanoparticles of linezolid by quality-by-design approach. J Drug Deliv Sci Technol 60:101976.
   Web of Science ®Google Scholar
• Patil KD, Bagade SB, Bonde SC. (2020). QbD-enabled stability-indicating assay method for the estimation of linezolid in newly developed gelatin nanoparticles for anti-tubercular therapy. Chromatographia 83:963–73.
   Web of Science ®Google Scholar
• Patil TS, Deshpande AS. (2021). Design, development, and characterisation of clofazimine-loaded mannosylated nanostructured lipid carriers: 33-Box-Behnken design approach. Mater Technol 36:460–75.
   Web of Science ®Google Scholar
• Ritger PL, Peppas NA. (1987). A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release 5:37–42.
   Google Scholar
• Trimukhe C, Patil P, Sheth K, et al. (2019). Studies on nanolipid emulgel of nimesulide for transdermal delivery. vol. 56. India: IMDA, 74–7.
   Google Scholar
• Wen H, Jung H, Li X. (2015). Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J 17:1327–40.
   PubMed Web of Science ®Google Scholar